Prosecution Insights
Prosecution Insights
Technology areas: Chemistry & Materials • Semiconductors, Circuits & Optics • Transportation, E-Commerce & Mechanical Systems • Medical Devices & Mechanical Engineering
11 pending office actions • 10 clients • 11 examiners • 9 art units • 0 of 11 (0%) have an AI response strategy ready
Adler Pollock & Sheehan P.C. is a patent law firm that specializes in Biotechnology & Pharmaceuticals, where it has managed 1383 career applications. The firm maintains a resolved allowance rate of 87.76 percent, reflecting its results in securing patent protection for life sciences innovations. This rate serves as a benchmark for their performance in this technical area.
The firm currently has 10 pending office actions. Their prosecution history shows an average of 2.91 office actions per allowance. This metric indicates an efficient prosecution process, typically requiring the rounds of interaction with examiners recorded in the data to reach a grant. Practitioners can use the 2.91 average to estimate the timeline and effort for new Biotechnology & Pharmaceuticals filings.
The 1383 career applications demonstrate the firm's experience in the industry. The 87.76 percent allowance rate and 2.91 office actions per allowance together describe a firm that is both successful and efficient in its prosecution efforts. The 10 pending office actions represent a portion of their current active workload.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (27%) |
| §103 only | 1 (9%) |
| §112 only | 2 (18%) |
| Multi-statute (no §101) | 5 (45%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ORTIZ, ADAM C | 1 | 65.9% | +34.6% |
| CHANG, OLIVIA C | 1 | 84.4% | +13.3% |
| MACCRATE, NICOLE PAIGE | 1 | 56.8% | +22.4% |
| MORALES, JON ERIC C | 1 | 85.4% | +10.0% |
| DOWNEY, JOHN R | 1 | 59.7% | +23.7% |
| CORNELIUS, CLAIRE ADRIENNE | 1 | 66.7% | +0.0% |
| STIGELL, THEODORE J | 1 | 78.3% | +14.9% |
| BOECKELMAN, JACOB A | 1 | 35.2% | +45.6% |
| WALTERS JR, ROBERT S | 1 | 51.5% | +50.4% |
| SMITH, DAVID E | 1 | 85.2% | +7.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17996489 | TIME-RESOLVING HYPERSPECTRAL IMAGING SPECTROSCOPY | SMITH, DAVID E | 97d overdue |
| 18957094 | MEMBRANE COVERED ATTRACTANT POD | MACCRATE, NICOLE PAIGE | 29d |
| 19248266 | LEVELING INFANT BED | ORTIZ, ADAM C | — |
| 18970680 | FUSION PLATE TO ASSIST FUSION OF A FIRST AND SECOND BONE | CHANG, OLIVIA C | — |
| 18951376 | HUMAN-POWERED STIMULATING/SENSING IMPLANT SYSTEM | MORALES, JON ERIC C | — |
| 18842001 | HYDROGEL CONDUCTIVITY IMPACTS SKIN DOSE FROM TUMOR TREATING FIELDS | DOWNEY, JOHN R | — |
| 18708467 | PREDICTING COVID-19 ANTIBODIES AMONG SURVIVORS WITH DEEP RNA SEQUENCING | CORNELIUS, CLAIRE ADRIENNE | — |
| 18557561 | DECELLULARIZED TISSUE HYDROGELS | BOECKELMAN, JACOB A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18638615 | ACCESS PORT SYSTEM WITH SELF-ADJUSTING CATHETER LENGTH | STIGELL, THEODORE J | 84d overdue |
| 18957094 | MEMBRANE COVERED ATTRACTANT POD | MACCRATE, NICOLE PAIGE | 29d |
| 19248266 | LEVELING INFANT BED | ORTIZ, ADAM C | — |
| 18970680 | FUSION PLATE TO ASSIST FUSION OF A FIRST AND SECOND BONE | CHANG, OLIVIA C | — |
| 18951376 | HUMAN-POWERED STIMULATING/SENSING IMPLANT SYSTEM | MORALES, JON ERIC C | — |
| 18842001 | HYDROGEL CONDUCTIVITY IMPACTS SKIN DOSE FROM TUMOR TREATING FIELDS | DOWNEY, JOHN R | — |
| 18557561 | DECELLULARIZED TISSUE HYDROGELS | BOECKELMAN, JACOB A | — |
| 18341067 | DENTAL ALIGNER | WALTERS JR, ROBERT S | — |
| Art Unit | Apps |
|---|---|
| 3673 | 1 |
| 3775 | 1 |
| 3642 | 1 |
| 2845 | 1 |
| 3783 | 1 |
| 1655 | 1 |
| 1717 | 1 |
| 2881 | 1 |
| 1798 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19248266 | LEVELING INFANT BED | Kids2, LLC | ORTIZ, ADAM C | 3673 | §103§112 | Final Rejection | — | Pending | Jun 24, 2025 |
| 18970680 | FUSION PLATE TO ASSIST FUSION OF A FIRST AND SECOND BONE | Arc Techtonics, Inc. | CHANG, OLIVIA C | 3775 | §102§112 | Non-Final OA | — | Pending | Dec 05, 2024 |
| 18957094 | MEMBRANE COVERED ATTRACTANT POD | American Insect Attractants LLC | MACCRATE, NICOLE PAIGE | 3642 | §102§103§112 | Final Rejection | 29d | Pending | Nov 22, 2024 |
| 18951376 | HUMAN-POWERED STIMULATING/SENSING IMPLANT SYSTEM | Evoke Medical, LLC Dba Directsync Surgical | MORALES, JON ERIC C | §101§102§103 | Non-Final OA | — | Pending | Nov 18, 2024 | |
| 18842001 | HYDROGEL CONDUCTIVITY IMPACTS SKIN DOSE FROM TUMOR TREATING FIELDS | Rhode Island Hospital | DOWNEY, JOHN R | 2845 | §102§103§112 | Non-Final OA | — | Pending | Aug 27, 2024 |
| 18708467 | PREDICTING COVID-19 ANTIBODIES AMONG SURVIVORS WITH DEEP RNA SEQUENCING | Rhode Island Hospital | CORNELIUS, CLAIRE ADRIENNE | §101§102§103§112 | Non-Final OA | — | Pending | May 08, 2024 | |
| 18638615 | ACCESS PORT SYSTEM WITH SELF-ADJUSTING CATHETER LENGTH | Imotik Biosolutions LLC | STIGELL, THEODORE J | 3783 | §103 | Non-Final OA | 84d overdue | Pending | Apr 17, 2024 |
| 18557561 | DECELLULARIZED TISSUE HYDROGELS | The University of Nottingham | BOECKELMAN, JACOB A | 1655 | §101§102§103§112 | Final Rejection | — | Pending | Oct 26, 2023 |
| 18341067 | DENTAL ALIGNER | BIXBY INTERNATIONAL CORPORATION | WALTERS JR, ROBERT S | 1717 | §112 | Non-Final OA | — | Pending | Jun 26, 2023 |
| 17996489 | TIME-RESOLVING HYPERSPECTRAL IMAGING SPECTROSCOPY | Research Instruments Corporation | SMITH, DAVID E | 2881 | §102§103 | Final Rejection | 97d overdue | Pending | Oct 18, 2022 |
| 17933986 | APPARATUS, METHOD, SYSTEM FOR THE DETERMINATION OF BLOODBORNE FACTORS INDICATIVE OF INFLAMMATION | Alcor Scientific LLC | TURK, NEIL N | 1798 | §112Other | Final Rejection | 4d overdue | Pending | Sep 21, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial